T/CHATA 021-2022 Active Group standards

T/CHATA 021-2022 Guidelines for treating patients with varying degrees of liver damage caused by anti-tuberculosis drugs

T/CHATA 021-2022 Guidelines for treating patients with varying degrees of liver damage caused by anti-tuberculosis drugs

Publish Date: 2022-02-24 Implement Date: 2022-02-24 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us
Price: $ 22.00
Out of stock

Basic Information

Standard Code: T/CHATA 021-2022
Standard Type: Group standards
Standard Status: Active
is_force_gb: no
CCS Name: Medicine
ICS Name: Integrated medical science and healthcare devices
Publish Date: 2022-02-24
Implement Date: 2022-02-24
Pages: 12 pages

Scope

This document provides the clinical grading of liver damage caused by anti-tuberculosis drugs, commonly used liver-protective drugs, grading treatment principles and schemes of liver-protective drugs for liver damage caused by anti-tuberculosis drugs, principles of adjusting anti-tuberculosis drug treatment, and guidelines for risk assessment and monitoring of liver damage.
This document is applicable to the management of drug-induced liver damage caused by anti-tuberculosis treatment or preventive treatment in tuberculosis patients or latent tuberculosis infection patients diagnosed by all levels and types of medical and health institutions.

Development Information

Word Count: 20 Thousand words Pages: 12 pages

Related Standards

Contact Us